Printer Friendly

SOCIETE GENERALE SECURITIES AND HEALTHCARE CAPITAL GROUP SPONSORING AMERICAN BIOGENETIC SCIENCES PRESENTATION TO MEET NEW COMPANY PRESIDENT

    Societe Generale Securities Corporation and Healthcare Capital Group cordially invites the media to attend a luncheon presentation on Thursday, Nov. 19 at noon at the Inter Continental Hotel, 111 East 48th Street, New York City, to introduce the management of American Biogenetic Sciences, Inc. (NASDAQ: MABXA).
    American Biogenetic Sciences, Inc. (ABS) is a biopharmaceutical company which conducts research at the University of Notre Dame, Indiana, Trinity College Dublin, Ireland and University College Galway, Ireland, to develop and commercialize monoclonal antibody-based products and unique testing systems for diagnosing, preventing and treating cardiovascular disease.  The company's enabling technologies are founded upon their proprietary germ -- free and virtually antigen free mouse colony.
    The luncheon will allow the media their first opportunity to meet the company's newly appointed President, Chief Operating Officer and Director, Kenneth H. Burk, Ph.D.  Dr. Burk has joined ABS's international network from Genelabs Technologies Inc., where his position was president of its subsidiary, Biotech Resources, Inc. (BTR). Prior to joining BTR, Dr. Burk spent eight years with Warner Lambert. He was promoted from senior research scientist to director of research and development where under his direction nine products were FDA approved and released.
    Dr. Burk's appointment comes at an exciting time for ABS, as a number of breakthrough products are in various stages of development. In the cardiovascular area, ABS has developed and received FDA approval on CADKIT, a proprietary and patented diagnostic which measures fibrogen levels in blood plasma.  An Investigational New Drug (IND) application has been filed with FDA seeking approval to begin human clinical trials on the company's proprietary and patented imaging agent that detects clots in the heart and lungs.  ABS presently has other research projects in various stages of development including a rapid, site specific antibody that can be used to deliver medication to dissolve clots.
    A question and answer period will follow the presentation.
    To RSVP or if you can't attend but want a copy of the presentation please call either.
    -0-             11~16~92
    CONTACT:  Fran Giambanco, senior vice president of American Biogenetic Sciences, 516-789-2600, or Phil Fried or Tom Jordan of The Dilenschneider Group, 212-922-0900, for American Biogenetic Sciences~
    PRNewswire -- Nov. 16
    (MABXA) CO:  AMERICAN BIOGENETIC SCIENCES, INC. IN:  MTC ST:  NY


-- NY016 -- X127 11~16~92
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 16, 1992
Words:376
Previous Article:INAMED REPORTS RECORD NINE MONTH SALES AND PROFITS
Next Article:NEW JERSEY BELL TO INSTALL ADVANCED FIBER NETWORK TO DELIVER TELEPHONE, CABLE TV AND INFORMATION SERVICES
Topics:


Related Articles
SOCIETE GENERALE SECURITIES CORPORATION & HEALTHCARE CAPITAL GROUP APPOINTED AMERICAN BIOGENETIC SCIENCES FINANCIAL ADVISORS
AMERICAN BIOGENETIC SCIENCES SENDS LETTER TO SHAREHOLDERS
ABS PREVIEWS CARDIOVASCULAR PRODUCTS
SOCIETE GENERALE SELECTS THE BANK OF NEW YORK FOR NEW SPONSORED ADR
SOCIETE GENERALE OFFICIALLY OPENS NEW U.S. HEADQUARTERS IN MANHATTAN; REAFFIRMS COMMITMENT TO THE U.S. MARKET
CAMBRIDGE HOLDING L.L.C. AND SOCIETE GENERALE ESTABLISH FINANCING AND JOINT MARKETING ARRANGEMENTS
SOCIETE GENERALE HIRES CURTIS R. WELLING
Press Release Societe Generale.
SG Cowen Expands Business to Include Consumer Growth Sector; Three Senior Bankers & Two Top Analysts Join SG Cowen From Robertson Stephens.
Media & Entertainment Team Adds to SG Cowen Strengths; Four Senior Bankers and Two Senior Analysts from Robertson Stephens Launch Media &...

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters